Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw
Oral Diseases · 2026-09 · 32 (9) · 2815-2825
DOI: 10.1111/odi.70331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 06.04.2026. Verfasst von Hae-Seo Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University, Cheonan, Republic of Korea. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Density Conservation Agents, Antibodies, Monoclonal, Bisphosphonate-Associated Osteonecrosis of the Jaw. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Objective
This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro. Materials and Methods Thirty‐five female C57BL/6 mice were divided into three groups: romosozumab followed by zoledronate (ROM+ ZOL), saline followed by zoledronate (ZOL), and control (Con) group receiving saline. After drug administration, the maxillary first molars were extracted. Bone healing and necrosis were evaluated using micro‐computed tomography, histomorphometry, and immunohistochemistry. To investigate the mechanism underlying the in vivo study results, the effects of romosozumab and zoledronate were evaluated by analysing tartrate‐resistant acid phosphatase staining and actin ring formation after differentiation of RAW 264.7 cells.
Results
The ROM+ZOL group exhibited more severe bone necrosis than the ZOL and Con groups. The ROM+ZOL group demonstrated a lower bone volume fraction and a reduction in the number of sclerostin‐positive cells, suggesting enhanced osteonecrosis when romosozumab was administered before zoledronate. Moreover, both zoledronate and romosozumab effectively suppressed osteoclast differentiation and function in vitro.
Conclusions
Sequential administration of romosozumab followed by zoledronate may exacerbate the risk of MRONJ, underscoring the need for careful consideration in clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University, Cheonan, Republic of Korea.
- Department of Oral Pathology, College of Dentistry, Gangneung-Wonju National University, Gangneung-si, Republic of Korea.
- The Shapiro Family Laboratory of Viral Oncology and Aging Research, Los Angeles, California, USA.
- UCLA Jonsson Comprehensive Cancer Centre, Los Angeles, California, USA.
ORCID-Profile: Hae-Seo Park, Reuben H Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Park, H. S., Kim, S., An, S. Y., Kim, R. H., Choi, J., & Kim, M. Y. (2026). Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw. Oral Diseases, 32(9), 2815-2825. https://doi.org/10.1111/odi.70331
Vancouver
Park HS, Kim S, An SY, Kim RH, Choi J, Kim MY. Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw. Oral Diseases. 2026;32(9):2815-2825. doi:10.1111/odi.70331
BibTeX
@article{Park2026,
author = {Park, Hae-Seo and Kim, Shihyun and An, Seo-Yeong and Kim, Reuben H and Choi, Jongho and Kim, Moon-Young},
title = {Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw},
journal = {Oral Diseases},
year = {2026},
volume = {32},
number = {9},
pages = {2815--2825},
doi = {10.1111/odi.70331}
}
EUVIMED